Elpida Therapeutics and BioSensics Announce Partnership to Advance Rare Disease Clinical Trials

Los Angeles, CA and Newton, MA – November 12, 2024  – Elpida Therapeutics, at the forefront in gene therapy for ultra-rare diseases, and BioSensics, a leader in wearable sensor and digital health technologies for clinical trials and research, are thrilled to announce a collaboration aimed at advancing clinical research in rare disease. The partnership will combine Elpida’s gene therapy expertise with BioSensics’ advanced digital health platforms and wearable sensor technologies to improve trial accuracy, enhance patient experience, and deliver meaningful insights into disease progression and intervention outcomes.

This collaboration will initially focus on integrating BioSensics’ technology within Elpida’s CMT4J trials, allowing for continuous, precise monitoring of patient activity and motor function remotely. By implementing wearable sensors, the initiative seeks to reduce the burden on patients and improve the real-time assessment of therapeutic outcomes. BioSensics’ technologies, widely recognized by the NIH and used across numerous neurological studies, will provide secure, compliant data collection through their cloud platform, BioDigit Cloud™ , enabling seamless data flow and enhancing protocol compliance.

“We are excited to leverage BioSensics’ state-of-the-art wearable technology to expand the reach of our trials,”said Terry Pirovolakis, CEO at Elpida Therapeutics. “This partnership represents a significant milestone in our mission to bring transformative therapies to the rare disease community.”

BioSensics, with its proven track record in clinical research for neuromuscular and neurodegenerative conditions, sees this collaboration as an opportunity to broaden its commitment to the rare disease field. 

“Elpida’s innovative gene therapy solutions align perfectly with our mission to support groundbreaking treatments for underserved communities,” said Ashkan Vaziri, PhD., CEO and Founder of BioSensics. “Together, we aim to pave the way for improved patient outcomes and expand the potential for wearable health technology in gene therapy trials.”

The partnership will extend to similar wearable solutions for other programs in Elpida’s pipeline, adding value to research efforts that aim to improve patient quality of life and long-term health outcomes through rigorous, data-driven methodologies.

About Elpida Therapeutics
Elpida Therapeutics is dedicated to delivering life-saving therapies for ultra-rare diseases. Founded to tackle the unmet medical needs of children living with rare conditions, Elpida works to rapidly advance its therapeutic programs in partnership with leading researchers and institutions around the globe. [www.elpidatx.com]

About BioSensics
BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults. BioSensics solutions and products have been deployed in more than 100 trials in 20 countries, including for collection of primary or secondary endpoints in more than 25 trials.

BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, NIH selected BioSensics to develop remote measure technologies for clinical trials in rare diseases. [www.BioSensics.com]